Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shape Therapeutics Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, so prosecution is divided between separate examination assignments.
SISSON, BRADLEY L is the busiest listed examiner, with 1 pending matter. Counsel should keep the responses distinct while checking that amendments and technical explanations remain compatible across the therapeutic portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SISSON, BRADLEY L | 1 | 19.7% | +20.5% |
| VYAS, KEYUR ANILKUMAR | 1 | 50.0% | +58.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920065 | Compositions and Methods Using SNRNA Components | VYAS, KEYUR ANILKUMAR | 5d overdue |
| 18255069 | HIGH THROUGHPUT RNA-EDITING SCREENING METHODS | SISSON, BRADLEY L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17920065 | Compositions and Methods Using SNRNA Components | VYAS, KEYUR ANILKUMAR | 5d overdue |
| 18255069 | HIGH THROUGHPUT RNA-EDITING SCREENING METHODS | SISSON, BRADLEY L | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18255069 | HIGH THROUGHPUT RNA-EDITING SCREENING METHODS | SISSON, BRADLEY L | 1682 | §103§112 | Non-Final OA | — | Pending | May 30, 2023 |
| 17920065 | Compositions and Methods Using SNRNA Components | VYAS, KEYUR ANILKUMAR | 1637 | §102§103 | Final Rejection | 5d overdue | Pending | Oct 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShape Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Bradley L Sisson has the most, with 1 of Shape Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
